News
CRMD
9.99
-0.65%
-0.07
Truist Financial Gives a Buy Rating to Cormedix (CRMD)
TipRanks · 2d ago
Cormedix (CRMD) Gets a Buy from RBC Capital
TipRanks · 3d ago
CorMedix Price Target Raised to $18.00/Share From $10.00 by Needham
Dow Jones · 3d ago
CorMedix Is Maintained at Buy by Needham
Dow Jones · 3d ago
Needham Maintains Buy on Cormedix, Raises Price Target to $18
Benzinga · 3d ago
CORMEDIX INC <CRMD.O>: RBC RAISES TARGET PRICE TO $11 FROM $9
Reuters · 3d ago
CorMedix Inc. Reports Q3 2024 Financial Results
TipRanks · 3d ago
CORMEDIX INC. AND SUBSIDIARIES FORM 10-Q FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024
Press release · 3d ago
Cormedix’s Growth Prospects Justify Buy Rating Despite Market Pressures
TipRanks · 3d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 3d ago
Alphabet, AMD report Q3 earnings beats: Morning Buzz
TipRanks · 3d ago
CorMedix Down Over 15%, On Pace for Largest Percent Decrease Since June 2023 -- Data Talk
Dow Jones · 3d ago
Strong Buy Recommendation for Cormedix Amid DefenCath’s Promising Market Trajectory and Strategic Partnerships
TipRanks · 3d ago
CorMedix Inc reports results for the quarter ended in January 1 - Earnings Summary
Reuters · 3d ago
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
NASDAQ · 3d ago
CORMEDIX Q3 OPERATING EXPENSES USD 14.1 MILLION
Reuters · 3d ago
Press Release: CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update
Dow Jones · 3d ago
Press Release: CorMedix Inc. Reports Third -2-
Dow Jones · 3d ago
CorMedix: Q3 Earnings Snapshot
Barchart · 4d ago
Here's the major earnings before the open tomorrow
Seeking Alpha · 4d ago
More
Webull provides a variety of real-time CRMD stock news. You can receive the latest news about Cormedix through multiple platforms. This information may help you make smarter investment decisions.
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.